Solvias offers Biologics characterization, impurities, potency and CMC quality testing. Services should be matched to the intended study and assay requirements.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The current website explicitly lists physicochemical, solid-state, and particle characterization, structure elucidation, and dissolution analysis for small molecules.
Biologics characterization, impurities, potency and CMC quality testing
Specialist contract research/testing services
Program / service
Target / indication
Representative stage
Evidence & scope
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
The current website confirms solid-state characterization. The current commercial scope for comprehensive salt, cocrystal, and polymorph screening requires reconfirmation.
Historical third-party supplier listings are not treated as a current complete service menu.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
